Oruka Therapeutics Reports Third Quarter 2024 Financial Results …
1 day ago — Third Quarter 2024 Financial Results. Cash Position:As of September 30, 2024, Oruka had available cash and cash equivalents of $410.9 million. Net cash used in operating activities was $27.8 ...
Positive Outlook for Oruka Therapeutics: Promising …
1 day ago — Oruka Therapeutics (ORKA) Company Description: ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases.
Oruka Therapeutics Reports Third Quarter 2024 Financial Results …
1 day ago — MENLO PARK, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported third quarter 2024 financial results and provided a corporate update.
Oruka Therapeutics Reports Third Quarter 2024 Financial
1 day ago — Third Quarter 2024 Financial Results. Cash Position: As of September 30, 2024, Oruka had available cash and cash equivalents of $410.9 million. Net cash used in operating activities was $27.8 ...
Oruka Therapeutics | A new era for chronic skin diseases
News. View All News. View Corporate Deck. Oruka is developing novel biologics that aim to offer the greatest possible freedom from disease to people affected by chronic skin conditions.
Oruka Therapeutics to Present at Multiple November Investor …
Nov 4, 2024 — Date: Monday, November 18 th, 2024. Time: 2:25PM ET. Jefferies London Healthcare Conference. Date: Wednesday, November 20 th, 2024. Time: 2:00PM GMT. A webcast and replay of Oruka’s presentation ...
Oruka Therapeutics Announces Closing of Merger with ARCA …
Sep 3, 2024 — Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions. Company on ...
Paragon Therapeutics Announces Oruka Therapeutics Has …
Apr 3, 2024 — Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and...
ARCA biopharma and Oruka Therapeutics Announce ...
Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F...
Oruka Therapeutics Reports Third Quarter 2024 Financial Results …
1 day ago — Cash Position: As of September 30, 2024, Oruka had available cash and cash equivalents of $410.9 million. Net cash used in operating activities was $27.8 million for the third quarter of 2024. The ...